Eisai Continues Alzheimer's Research, Adds 2 Alzheimer's Pros as Execs

The industry was shaken up when Tokyo-based Eisai and its collaboration partner, Biogen, announced they were abandoning huge swaths of their Alzheimer’s program related to aducanumab in late March.